Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova

Inclusion Criteria:

• Subjects will be outpatients between the ages of 18 and 72.

• Subjects must have a biopsy-proven diagnosis of ulcerative colitis for greater thanthree months.

• There should be evidence of active disease with a total Mayo score of 6 to 10 points (scores range from 0 to 12, with higher scores indicating more severe diseaseactivity).

• There should be moderate (marked erythema, lack of vascular pattern, friability,erosions) to severe (spontaneous bleeding, ulceration) active disease on colonoscopy (Mayo endoscopic score of at least 2) at time of enrollment.

• Laboratory inclusion criteria will require a hemoglobin level of >9.0 g/dL, a whiteblood count between 5,000 and 15,000/μL, a platelet count of >100,000μL, a blood ureanitrogen < 40mg/dL, a serum creatinine of <2.0mg/dL, a total bilirubin < 2.5 mg/dL,and an alkaline phosphatase of <250U/dL.

• Women will be required to have a negative urine pregnancy test and to practice birthcontrol.

• The following medications will be allowed and continued throughout the study: Oral orrectal sulfasalazine, mesalamine, or mesalamine derivative (maintenance therapy of > 8weeks, stable dose of > 4 weeks); Oral corticosteroid (prednisone, prednisolone, orbudesonide) at an equivalent dose of a maximum of 40mg daily prednisone (maintenancetherapy of >4 weeks, stable dose of > 2 weeks), azathioprine or 6-mercaptopurine (maintenance therapy of > 8 weeks, stable dose of > 4 weeks).

• Subjects must have the ability to provide informed consent and be willing to keep allscheduled appointments for the duration for the study period.

Exclusion Criteria:

• Inpatients, pregnant patients, patients with impaired cognition, patients with ahistory of active substance abuse in the past six months, and children.

• Patients with a history of bowel surgery in the prior six months or who currently orpreviously had an ileostomy or colostomy.

• Patients with active malignancy or treatment with anticancer drugs in the past 5years, have a history of colorectal cancer or dysplasia, or a history of neoplasm ofthe gastrointestinal tract.

• Female patients who are pregnant, breastfeeding, wishing to become pregnant duringstudy participation, or unwilling to use birth control.

• Patients with white blood count <5,000 or >15,000/mm3; platelet count <150,000 per μl;or iron or vitamin B12 deficiency. Correction of lab exclusion is allowed providedthat medical condition is not deemed to put patient at risk and stability of result issustained for a minimum of 30 days.

• Patients with stools positive for enteric pathogens, ova, or parasites at Screening

• Patients with active hepatitis B virus or hepatitis C virus infection or have beenexposed to human immunodeficiency virus (HIV).

• Patients who have received an anti-tumor necrosis factor inhibitor (e.g. infliximab)within 12 weeks prior to Screening

• Patients who have received antibiotic, antifungal or antiparasitic medication in thelast 2 weeks prior to Screening and/or would potentially require this during the studytreatment period.

• Patients with evidence of poor compliance with medical advice and instructionincluding diet or medication.

• Patients who are unable or unwilling to swallow study medication suspension.

• Patients will be excluded if they have previously attempted helminthic therapy.

• There must not be evidence of fulminant colitis or a Mayo score of greater than 10

• Patients will be excluded if other clinically significant disease is present thatcould interfere with protocol compliance or interpretation of the results.